Curated News
By: NewsRamp Editorial Staff
September 03, 2025
Kairos Pharma Presents Breakthrough Lung Cancer Therapy Data at World Conference
TLDR
- Kairos Pharma's ENV105 Phase 1 data presentation offers investors early insight into a potential breakthrough therapy for drug-resistant lung cancer.
- ENV105 targets CD105 protein to reverse drug resistance and restore effectiveness of standard cancer therapies through combination with osimertinib.
- This therapy addresses significant unmet medical needs by potentially improving outcomes for patients with advanced EGFR-mutated non-small cell lung cancer.
- Initial Phase 1 data for ENV105 in lung cancer will be presented at the World Lung Cancer Conference in Barcelona this September.
Impact - Why it Matters
This development matters because lung cancer remains one of the deadliest cancers worldwide, with non-small cell lung cancer accounting for approximately 85% of all cases. Drug resistance is a major challenge in cancer treatment, often leading to treatment failure and disease progression. Kairos Pharma's ENV105 represents a novel approach that could potentially overcome this resistance mechanism, offering hope for improved survival rates and better quality of life for lung cancer patients. If successful, this therapy could transform standard cancer treatment protocols and provide new options for patients who have developed resistance to existing therapies, addressing a critical unmet medical need in oncology.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a Los Angeles-based clinical-stage biopharmaceutical company, has announced its participation in the prestigious World Lung Cancer Conference in Barcelona, Spain, scheduled for September 6-9, 2025. The company will present groundbreaking initial Phase 1 data for its innovative cancer therapeutic ENV105, specifically targeting non-small cell lung cancer patients with EGFR mutations. Principal Investigator Dr. Karen Reckamp will deliver a presentation titled "Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Patients," highlighting the promising combination therapy approach that aims to address drug resistance in cancer treatment.
The clinical trial represents a significant advancement in oncology therapeutics, focusing on ENV105's mechanism of targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. This antibody-based therapy works by reversing drug resistance that typically develops in response to standard cancer therapies, potentially restoring the effectiveness of existing treatments and preventing disease relapse. Kairos Pharma's approach utilizes structural biology to overcome both drug resistance and immune suppression in cancer, positioning ENV105 as a potential game-changer for multiple cancer types. The company currently has ENV105 in Phase 2 trials for castrate-resistant prostate cancer alongside the ongoing Phase 1 lung cancer study, addressing critical unmet medical needs in oncology.
For investors and stakeholders seeking comprehensive information, the latest updates and news regarding KAPA are available through the InvestorBrandNetwork, which provides advanced wire-grade press release syndication and corporate communications solutions. The full press release detailing this significant development can be accessed at https://ibn.fm/5JjZJ, offering complete insights into this promising cancer therapeutic advancement and its potential impact on the future of oncology treatment.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Presents Breakthrough Lung Cancer Therapy Data at World Conference
